The therapeutic efficacy of PD-1 mAb on tumor growth was almost completely abolished by co-administration of neutralizing Abs against IFNAR1 and TNFR (Fig. 7c and Supplementary Fig. S6b–d). The gene discussed is TNFRSF1A; the disease is neoplasm.